609 related articles for article (PubMed ID: 27960627)
1. Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
Park C; Kwon EY; Choi SM; Cho SY; Byun JH; Park JY; Lee DG; Kang JH; Shin J; Kim H
Hum Vaccin Immunother; 2017 May; 13(5):1169-1176. PubMed ID: 27960627
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
3. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.
Simell B; Nurkka A; Ekström N; Givon-Lavi N; Käyhty H; Dagan R
Clin Vaccine Immunol; 2012 Oct; 19(10):1618-23. PubMed ID: 22875604
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.
Xie J; Zhang Y; Caro-Aguilar I; Indrawati L; Smith WJ; Giovarelli C; Winters MA; MacNair J; He J; Abeygunawardana C; Musey L; Kosinski M; Skinner JM
Pediatr Infect Dis J; 2020 Jan; 39(1):70-77. PubMed ID: 31725555
[TBL] [Abstract][Full Text] [Related]
5. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP
Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides.
Tan CY; Immermann FW; Sebastian S; Pride MW; Pavliakova D; Belanger KA; Watson W; Scott DA; Sidhu M; Jansen KU; Giardina PC
mSphere; 2018 Aug; 3(4):. PubMed ID: 30089644
[TBL] [Abstract][Full Text] [Related]
8. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
9. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
11. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
[TBL] [Abstract][Full Text] [Related]
13. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.
Juergens C; Patterson S; Trammel J; Greenberg D; Givon-Lavi N; Cooper D; Gurtman A; Gruber WC; Scott DA; Dagan R
Clin Vaccine Immunol; 2014 Sep; 21(9):1277-81. PubMed ID: 24990907
[TBL] [Abstract][Full Text] [Related]
14. Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children.
Cho HK; Park IH; Burton RL; Kim KH
J Korean Med Sci; 2016 Jun; 31(6):950-6. PubMed ID: 27247505
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
[TBL] [Abstract][Full Text] [Related]
19. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
